AB1162 COMPARISON OF SERUM CXCL13 LEVELS BETWEEN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS
Authors: D. Yildirim, I. Vasi, M. Baykul, M. Gulengul, Y. Edek, H. Küçük, H. Karadeniz, E. Adisen, A. Erden, A. Tufan, B. Goker, K. Nas, M. A. Ozturk
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Psoriasis is a chronic, autoimmune disease with predominantly skin and joint involvement. Factors leading to the progression of psoriasis to psoriatic arthritis (PsA) is still a mystery in spite of an increasing number of in vivo and in vitro studies. CXCL-13, a B cell chemokine, studied and emphasized in lymphoid pathways, immune responses and pathogenesis of many rheumatologic diseases [1-2]. Moreover, this chemokine is associated with systemic involvement of rheumatic diseases such as lupus nephritis [3]. <h3>Objectives</h3> The aim of the study was to evaluate serum CXCL 13 levels in patients with psoriasis and psoriatic athritis and compare with healthy controls. <h3>Methods</h3> 54 patients with psoriasis and 47 patients with psoriatic arthritis and 19 controls were enrolled to the study. Blood samples from study participants were collected and serum CXCL-13 levels were analysed with ELISA method via Human BLC(CXCL 13) kit (BT Lab, Shangai, China). <h3>Results</h3> Age, body mass index and serum PASI scores were similar between two patient groups; but higher when compared to controls (Table 1). Median levels of CXCL-13 levels were significantly higher in patients with psoriatic arthritis and psoriasis when compared to control group (p= 0,001, Figure 1). But serum CXCL-13 levels were similar between psoriasis and psoriatic arthritis groups (p=0,251). Also levels of C reactive protein and sedimentation were higher in patients with psoriatic arthritis, followed by psoriasis and controls (p= 0.024 and 0.02, in order). <h3>Conclusion</h3> Many clinical studies showed that CXCL13 expression is elevated in many autoimmune conditions and related to activity, prognosis and symptomatic status of disease [4]. Also in SLE, this chemokine was associated with extraarticular involvement of disaese [5]. Also previous studies reported increased levels of serum and tissue CXCL-13 in psoriasis and associated with disease severity [6]. We conclude that serum levels of CXCL-13 is associated with psoriasis, but not related with articular involvement. <h3>References</h3> [1]Nerviani A, Pitzalis C. Role of chemokines in ectopic lymphoid structures formation in autoimmunity and cancer. J Leukoc Biol. 2018 Aug;104(2):333-341. [2]Corsiero E, Nerviani A, Bombardieri M, Pitzalis C. Ectopic Lymphoid Structures: Powerhouse of Autoimmunity. Front Immunol. 2016 Oct 17;7:430. [3]Lee HT, Shiao YM, Wu TH, Chen WS, Hsu YH, Tsai SF, Tsai CY. Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis. J Rheumatol. 2010 Jan;37(1):45-52. [4]Rosengren S, Wei N, Kalunian KC, Kavanaugh A, Boyle DL. CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis. Rheumatology (Oxford). 2011 Mar;50(3):603-10. [5]Schiffer L, Worthmann K, Haller H, Schiffer M. CXCL13 as a new biomarker of systemic lupus erythematosus and lupus nephritis - from bench to bedside? Clin Exp Immunol. 2015 Jan;179(1):85-9. [6]Liu W, Zhou X, Wang A, Ma J, Bai Y. Increased peripheral helper T cells type 17 subset correlates with the severity of psoriasis vulgaris. Immunol Lett. 2021 Jan;229:48-54 <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.